Reports for APOTEX INC
Formerly known as AA PHARMA INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
26 (7%)
Discontinued:
343 (93%)
Reversed:
0 (0%)
369
145 (4%)
73 (30%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2024-10-10 | 2025-02-14 | 239819 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2019-12-12 | 2020-03-27 | 101097 |
| APO-RISPERIDONE | 0.25MG | TABLET | Resolved | 2017-08-31 | 2017-11-30 | 20707 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2023-05-19 | 2023-08-04 | 192803 |
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2017-12-14 | 2018-05-14 | 32827 |
| APO-RISPERIDONE | 1.0MG | TABLET | Resolved | 2020-01-22 | 2020-03-27 | 103920 |
| APO-RIVAROXABAN | 15MG | TABLET | Resolved | 2024-05-24 | 2024-08-09 | 228801 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2019-07-03 | 2019-10-07 | 88360 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2021-07-05 | 2021-12-03 | 141854 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Actual shortage | 2024-11-29 | 2025-02-06 | 244209 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2023-09-28 | 2024-01-05 | 205501 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2024-03-08 | 2024-05-10 | 221729 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2017-09-04 | 2019-10-15 | 20900 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2019-06-05 | 2019-10-07 | 85610 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2017-03-11 | 2017-05-18 | 487 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2024-09-20 | 2024-10-04 | 238239 |
| APO-RIVASTIGMINE | 1.5MG | CAPSULE | Resolved | 2023-07-21 | 2024-01-05 | 199518 |
| APO-RIVASTIGMINE | 6MG | CAPSULE | Resolved | 2017-07-26 | 2018-03-27 | 17322 |
| APO-RIVASTIGMINE | 4.5MG | CAPSULE | Resolved | 2018-01-22 | 2018-01-22 | 36947 |
| APO-RIVASTIGMINE | 3MG | CAPSULE | Resolved | 2019-06-12 | 2019-10-07 | 86336 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 4.5MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110974 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 9MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110977 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |